These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 25881636)

  • 1. After 10 Years of Clinical Trials with Liraglutide in Diabetes, What do we Know About its Effects on Clinical Cardiovascular Outcomes?
    Doggrell SA
    Rev Recent Clin Trials; 2015; 10(1):68-77. PubMed ID: 25881636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Results of the LEADER study: current evidence and perspectives in research].
    Mannucci E
    G Ital Cardiol (Rome); 2016 Dec; 17(12 Suppl 2):28S-31. PubMed ID: 28151519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial.
    Athyros VG; Katsiki N; Tentolouris N
    Curr Vasc Pharmacol; 2016; 14(5):469-473. PubMed ID: 27633290
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiovascular safety and benefits of GLP-1 receptor agonists.
    Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practice pearl: liraglutide and cardiovascular and renal events in type 2 diabetes.
    Guthrie R
    Postgrad Med; 2018 Mar; 130(2):154-158. PubMed ID: 29350569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?].
    Scheen AJ; Paquot N
    Rev Med Liege; 2018 Jan; 73(1):43-50. PubMed ID: 29388411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular safety of liraglutide for the treatment of type 2 diabetes.
    Chudleigh RA; Bain S
    Expert Opin Drug Saf; 2017 May; 16(5):627-635. PubMed ID: 28387138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liraglutide for Type 2 diabetes and obesity: a 2015 update.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Rev Cardiovasc Ther; 2015; 13(7):753-67. PubMed ID: 26106933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients.
    Madsbad S
    Expert Rev Cardiovasc Ther; 2019 May; 17(5):377-387. PubMed ID: 31055989
    [No Abstract]   [Full Text] [Related]  

  • 10. GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
    Simó R; Hernández C
    Diabetes; 2017 Jun; 66(6):1453-1460. PubMed ID: 28533296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].
    Reboldi G
    G Ital Cardiol (Rome); 2009 Jul; 10(7):434-47. PubMed ID: 19761101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The extra-glycemic effects of liraglutide: focus on cardiometabolic markers].
    Giglio RV; Patti AM; Nikolic D; Castellino G; Noto M; Parrino A; Montalto G; Rizzo M
    G Ital Cardiol (Rome); 2016 Apr; 17(4):253-8. PubMed ID: 27093208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
    Doggrell SA
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):371-377. PubMed ID: 29439603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is treatment with liraglutide efficient?
    Mezquita Raya P; Reyes García R
    Endocrinol Nutr; 2014 Apr; 61(4):202-8. PubMed ID: 24071060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide in a real-world setting: Joint modeling of metabolic response, prediction of efficacy, and cardiovascular risk.
    Alonso-Troncoso I; Carollo-Limeres C; Rios-Prego M; Guler I; Cadarso-Suárez C; F-Mariño A
    Endocrinol Diabetes Nutr (Engl Ed); 2019; 66(6):376-384. PubMed ID: 30528642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liraglutide for treating type 1 diabetes.
    Dejgaard TF; Frandsen CS; Holst JJ; Madsbad S
    Expert Opin Biol Ther; 2016; 16(4):579-90. PubMed ID: 26926662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials.
    Kaul S
    Diabetes Care; 2017 Jul; 40(7):821-831. PubMed ID: 28637887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Effects of Liraglutide.
    Mikhail N
    Curr Hypertens Rev; 2019; 15(1):64-69. PubMed ID: 29737256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations.
    Blumer I; Pettus JH; Santos Cavaiola T
    Postgrad Med; 2018 May; 130(4):375-380. PubMed ID: 29521173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.